Patents by Inventor John Termini

John Termini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11835499
    Abstract: Methods of quantifying a N2-(1-carboxyethyl)-2?-deoxyguanosine (CEdG) and N2-(1-carboxyethyl)-guanosine (CEG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of metabolic disorders or complications associated therewith, including diabetes, its associated complications, and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG and CEG levels before and after treatment. Measurement of CEdG and CEG levels is achieved by using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: December 5, 2023
    Assignee: CITY OF HOPE
    Inventors: Timothy W. Synold, John Termini, Sarah Shuck
  • Publication number: 20220331273
    Abstract: Methods of quantifying a N2-(1-carboxyethyl)-2?-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of metabolic disorders or complications associated therewith, including diabetes, its associated complications, and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels is achieved by using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Application
    Filed: November 22, 2021
    Publication date: October 20, 2022
    Applicant: CITY OF HOPE
    Inventors: Samuel RAHBAR, Timothy W. SYNOLD, John TERMINI, Gerald WUENSCHELL, Daniel TAMAE, Sarah SHUCK
  • Patent number: 11266618
    Abstract: Methods of quantifying N2-carboxyethyl-2?-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of disorders, including diabetes and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels occurs using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: March 8, 2022
    Assignee: CITY OF HOPE
    Inventors: Samuel Rahbar, Timothy W. Synold, John Termini, Daniel Tamae, Gerald Wuenschell
  • Patent number: 11179361
    Abstract: Methods of quantifying a N2-(1-carboxyethyl)-2?-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of metabolic disorders or complications associated therewith, including diabetes, its associated complications, and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels is achieved by using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: November 23, 2021
    Assignee: CITY OF HOPE
    Inventors: Samuel Rahbar, Timothy W. Synold, John Termini, Gerald Wuenschell, Daniel Tamae
  • Publication number: 20200363381
    Abstract: Methods of quantifying a N2-(1-carboxyethyl)-2?-deoxyguanosine (CEdG) and N2-(1-carboxyethyl)-guanosine (CEG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of metabolic disorders or complications associated therewith, including diabetes, its associated complications, and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG and CEG levels before and after treatment. Measurement of CEdG and CEG levels is achieved by using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Application
    Filed: July 31, 2020
    Publication date: November 19, 2020
    Applicant: CITY OF HOPE
    Inventors: Samuel RAHBAR, Timothy W. SYNOLD, John TERMINI, Sarah SHUCK
  • Patent number: 10314284
    Abstract: A liner or pad is configured to be positioned on a bottom surface of a metabolic cage or to form a bottom of a metabolic cage so as to provide a surface that comfortably supports a confined animal in the cage. The pad provides a surface that prevents the mouse from directly contacting the wire mesh bottom of the cage.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: June 11, 2019
    Assignee: City of Hope
    Inventors: John Termini, Timothy R. O'Connor, Miro Rusnak, Yin S. Chan
  • Publication number: 20180338939
    Abstract: Methods of quantifying a N2-(1-carboxyethyl)-2?-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of metabolic disorders or complications associated therewith, including diabetes, its associated complications, and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels is achieved by using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Application
    Filed: February 2, 2018
    Publication date: November 29, 2018
    Inventors: Samuel RAHBAR, Timothy W. SYNOLD, John TERMINI, Sarah SHUCK
  • Publication number: 20180207116
    Abstract: Methods of quantifying N2-carboxyethyl-2?-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of disorders, including diabetes and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels occurs using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Application
    Filed: December 29, 2017
    Publication date: July 26, 2018
    Inventors: Samuel Rahbar, Timothy W. Synold, John Termini
  • Patent number: 9855233
    Abstract: Methods of quantifying a N2-carboxyethyl-2?-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of disorders, including diabetes and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels occurs using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: January 2, 2018
    Assignee: CITY OF HOPE
    Inventors: Samuel Rahbar, Timothy W. Synold, John Termini
  • Publication number: 20160309677
    Abstract: A liner or pad is configured to be positioned on a bottom surface of a metabolic cage or to form a bottom of a metabolic cage so as to provide a surface that comfortably supports a confined animal in the cage. The pad provides a surface that prevents the mouse from directly contacting the wire mesh bottom of the cage.
    Type: Application
    Filed: April 19, 2016
    Publication date: October 27, 2016
    Inventors: John Termini, Timothy R. O' Connor, Miro Rusnak, Yin S. Chan
  • Publication number: 20150290156
    Abstract: Methods of quantifying a N2-carboxyethyl-2?-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of disorders, including diabetes and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels occurs using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Application
    Filed: November 7, 2014
    Publication date: October 15, 2015
    Inventors: Samuel RAHBAR, Timothy W. SYNOLD, John TERMINI
  • Publication number: 20120071559
    Abstract: Methods of quantifying a N2-carboxyethyl-2?-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of disorders, including diabetes and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels occurs using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Application
    Filed: November 30, 2011
    Publication date: March 22, 2012
    Inventors: Samuel Rahbar, Timothy W. Synold, John Termini
  • Publication number: 20100102218
    Abstract: Methods of quantifying a N2-carboxyethyl-2?-deoxyguanosine (CEdG) levels in biological samples and comparing those levels to known normal levels can diagnose a number of disorders, including diabetes and cancer. Methods can also determine whether therapies for disorders are effective by measuring CEdG levels before and after treatment. Measurement of CEdG levels occurs using liquid chromatography electrospray ionization tandem mass spectrometry.
    Type: Application
    Filed: August 10, 2009
    Publication date: April 29, 2010
    Inventors: Samuel Rahbar, Timothy W. Synold, John Termini